<DOC>
	<DOCNO>NCT00015964</DOCNO>
	<brief_summary>RATIONALE : Biological therapy ZD 1839 may interfere growth tumor cell slow growth head neck cancer . PURPOSE : Phase II trial study effectiveness ZD1839 treat patient metastatic recurrent cancer head neck .</brief_summary>
	<brief_title>ZD 1839 Treating Patients With Metastatic Recurrent Cancer Head Neck</brief_title>
	<detailed_description>OBJECTIVES : I . Determine activity ZD 1839 patient metastatic recurrent squamous cell carcinoma head neck . II . Determine effectiveness regimen patient . III . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive oral ZD 1839 daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 22-46 patient accrue study within 1-2 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm metastatic recurrent squamous cell carcinoma head neck incurable surgery radiotherapy At least 1 lesion measurable least 1 dimension At least 20 mm conventional technique OR At least 10 mm CT scan No known brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Karnofsky 60100 % Life expectancy : More 3 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin normal AST/ALT great 2.5 time upper limit normal Renal : Creatinine great 1.5 mg/dL Cardiovascular : No symptomatic congestive heart failure No unstable angina pectoris No cardiac arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No history allergic reaction compound similar chemical biological composition ZD 1839 No active infection No uncontrolled illness No psychiatric illness social situation would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior epidermal growth factor receptorbased therapy recurrent disease Chemotherapy : No 1 prior adjuvant neoadjuvant chemotherapy and/or chemoradiotherapy regimen At least 4 week since prior chemotherapy ( 6 week nitrosoureas mitomycin ) recover Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics See Chemotherapy At least 4 week since prior radiotherapy recover Surgery : See Disease Characteristics Other : No 1 prior regimen recurrent disease No concurrent investigational agent No concurrent combination antiretroviral therapy HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
</DOC>